Monkeypox
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- An infection that is caused by an Orthopoxvirus, which is transmitted by primates or rodents, and which is characterized by a prodromal syndrome of fever, chills, headache, myalgia, and lymphedema; initial symptoms are followed by a generalized papular rash that typically progresses from vesiculation through crusting over the course of two weeks.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Monkeypox
- Therapeutic area
- Infectious Disease
- monkeypox
- Monkeypox (Mpox)
- Monkeypox virus infection
- Mpox (Monkeypox)
- Mpox, Monkeypox
- infections, Monkeypox virus
- Disease mechanisms
- Acquired
Sources for recorded values
- All therapeutic areas
- Infectious Disease
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0002594
- Parent condition
- MONDO:0100329
Related records
Broader conditions (7)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Primary viral infectious disease
- Viral infectious disease
Trials (73)
- A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
- A One Health Study of Monkeypox Human Infection
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
- A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
- A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
- A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
- An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC
- Assessing the Preparedness and Knowledge of Pharmacists in the Current Monkeypox Outbreak
- Assessment of Immune Memory - Humoral and Cellular - in mPOX-infected Patients : an Ancillary Study of the ANRS0258s MOSAIC Cohort
- Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC
- Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease
- Break-through Infection Following Mpox vaccinatIon
- Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
- Clinical and Biological Aspects of the MONKEYPOX Disease
- Clinical, Virological, Immunological, Psychosocial and Epidemiological Consequences of Human Monkeypox Virus (ProMPX)
- Cohort Study of Healthcare Workers Receiving Imvanex®
- Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
- DiagRaMIE Mpox Virus-RDC for the Diagnostic of Monkeypox
- Efficacy and Acceptability of a Monkeypox Curriculum for Disproportionately Impacted Communities
- Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia
Approved drugs (2)
- Tecovirimat monohydrate
- Vaccinia virus, live modified